Diakonos Oncology to Present at Biotech Showcase 2025 | PR Newswire [Video]

, /PRNewswire/ — Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, announced that it will present its latest developments at the Biotech Showcase in San Francisco, CA from January 13-15, 2025. Biotech Showcase is a premier event for private and micro-mid-cap biotechnology companies to highlight their innovation and connect with global investors and engage with executives from prominent biopharmaceutical interests.

Diakonos Oncology will be represented by President and Chief Operating Officer Jay Hartenbach, who will be presenting on recent corporate milestones and research developments, including lead product DOC1021, a unique autologous dendritic cell vaccine (DCV), which will begin enrolling patients in its Phase 2 clinical trial for glioblastoma (GBM) in H1 2025 at leading treatment centers across the US.

Details of the presentation are as follows:

Event: Biotech Showcase 2025

Date: January 15, 2025, at 11:15 a.m. Pacific Standard …